G007-LK Tankyrase 1/2 Inhibitor: Precise Tool for Wnt/β-Catenin Pathway Modulation

Executive Summary: G007-LK is a highly selective inhibitor of tankyrase 1 and 2 (TNKS1/2), with IC50 values of 46 nM and 25 nM, respectively, in biochemical assays (Jia et al., 2017). The compound robustly suppresses Wnt/β-catenin signaling in Wnt3a-stimulated HEK 293 cells (IC50 = 0.05 μM for ST-Luc reporter activity) (APExBIO). In APC-mutant colorectal cancer models, G007-LK induces dynamic degradasome formation, driving β-catenin degradation and stabilizing AXIN1/2. In vivo, G007-LK significantly inhibits tumor growth and reduces TNKS1/2 and β-catenin protein levels in xenograft mouse models. The compound is recommended for research on Wnt/β-catenin and Hippo pathway crosstalk, with validated use in colorectal and hepatocellular carcinoma models (Jia et al., 2017).

Biological Rationale

Tankyrases (TNKS1/2) are poly(ADP-ribose) polymerases (PARPs) implicated in Wnt/β-catenin signaling, telomere maintenance, and cell cycle regulation (Jia et al., 2017). Overexpression or hyperactivity of tankyrases can lead to aberrant β-catenin stabilization, a hallmark of APC-mutant colorectal cancer and a driver of uncontrolled proliferation in several solid tumors. Tankyrases also regulate Hippo pathway components, modulating the activity of Yes-associated protein (YAP), a critical oncogenic transcriptional co-activator (Jia et al., 2017).

Inhibition of tankyrases disrupts Wnt/β-catenin signaling by stabilizing AXIN1/2, leading to β-catenin phosphorylation, ubiquitination, and proteasomal degradation. This effect is critical for APC-mutant tumor cell lines where β-catenin escape drives proliferation. In hepatocellular carcinoma (HCC), tankyrase inhibitors modulate the Hippo cascade by stabilizing Angiomotin-like proteins (AMOTL1/2), leading to YAP inactivation and suppression of tumor growth (Jia et al., 2017).

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK binds competitively to the catalytic PARP domain of TNKS1 and TNKS2, inhibiting their auto-poly(ADP-ribosyl)ation activity (IC50: 46 nM for TNKS1, 25 nM for TNKS2, in vitro) (APExBIO). This inhibition leads to stabilization of AXIN1/2, key scaffolding proteins of the β-catenin destruction complex. The stabilized complex facilitates phosphorylation of β-catenin by GSK3β, which is then recognized by β-TrCP for ubiquitin-mediated proteasomal degradation.

In cellular systems, G007-LK induces the assembly of degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin. This rapidly reduces cytosolic and nuclear β-catenin levels, suppressing Wnt target gene transcription. In addition to targeting Wnt signaling, G007-LK stabilizes AMOTL1/2, thereby inhibiting nuclear translocation and activity of YAP, a regulator of the Hippo pathway (Jia et al., 2017).

Evidence & Benchmarks

• G007-LK inhibits auto-poly(ADP-ribosyl)ation of TNKS1 (IC50 = 46 nM) and TNKS2 (IC50 = 25 nM) in biochemical assays (APExBIO).
• In Wnt3a-induced HEK 293 cells, G007-LK suppresses ST-Luc Wnt signaling reporter activity with an IC50 of 0.05 μM (APExBIO).
• In APC-mutant SW480 colorectal cancer cells, G007-LK induces degradasomes and reduces both cytosolic and nuclear β-catenin, as shown by immunofluorescence and Western blotting (Jia et al., 2017).
• In vivo, G007-LK inhibits colorectal tumor growth and reduces TNKS1/2 and β-catenin protein levels in COLO-320DM xenograft mouse models (APExBIO).
• In hepatocellular carcinoma cell lines, G007-LK downregulates YAP protein levels, upregulates AMOTL1/2, and suppresses YAP/TEAD reporter activity (Jia et al., 2017).
• Tankyrase inhibitors, including G007-LK, can synergize with MEK and AKT inhibitors to further suppress HCC cell proliferation (Jia et al., 2017).

This article extends the mechanistic detail discussed in G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β... by providing updated benchmarks and clarifying AXIN1/2 stabilization as a validated endpoint.

It also updates the application-focused guidance in G007-LK: A Specific Tankyrase Inhibitor for Wnt Signaling... by integrating Hippo pathway data and workflow integration tips for reproducible results.

Applications, Limits & Misconceptions

G007-LK (APExBIO, SKU B5830) is primarily used in research on Wnt/β-catenin and Hippo pathway modulation, focusing on APC-mutant colorectal cancer and hepatocellular carcinoma models. It is also a reference inhibitor for dissecting β-catenin degradation mechanisms and for evaluating pathway crosstalk in vitro and in vivo. For comprehensive protocol troubleshooting, see Optimizing Cell Assays with G007-LK Tankyrase 1/2 Inhibit..., which this article complements by mapping precise selectivity and stability data.

Common Pitfalls or Misconceptions

• G007-LK is highly soluble in DMSO (≥26.5 mg/mL), but insoluble in water and ethanol; improper solvent use can reduce efficacy (APExBIO).
• It is not effective for wild-type β-catenin driven tumors lacking upstream pathway activation.
• G007-LK is for research use only and not for clinical administration.
• Long-term storage of G007-LK stock solutions (even in DMSO) can compromise compound integrity; always store solid at -20°C.
• In vivo dosing should be guided by validated mouse xenograft protocols; extrapolation to other species requires independent validation (Jia et al., 2017).

Workflow Integration & Parameters

For cell-based assays, prepare G007-LK stock solutions in DMSO at concentrations up to 26.5 mg/mL. Warm to 37°C or use an ultrasonic bath to ensure complete dissolution. Dilute into culture media immediately prior to use; maintain final DMSO concentrations below 0.1% v/v to minimize cytotoxicity. For in vivo studies, follow published xenograft dosing regimens and monitor for tumor growth inhibition and β-catenin protein reduction (Jia et al., 2017).

Store G007-LK as a dry powder at -20°C. Avoid repeated freeze-thaw cycles of solutions. For optimal reproducibility, use validated controls (e.g., Wnt3a stimulation, APC-mutant cell lines, parallel MEK/AKT inhibitor arms). For ordering, see the B5830 kit from APExBIO.

Conclusion & Outlook

G007-LK is a validated, potent, and selective tankyrase 1/2 inhibitor for dissecting Wnt/β-catenin and Hippo pathway function in cancer models. Its nanomolar activity, robust β-catenin degradation induction, and in vivo efficacy position it as a gold-standard research tool for APC mutation colorectal cancer and hepatocellular carcinoma studies. Future work may extend its applications to combinatorial pathway targeting and precision oncology research (Jia et al., 2017).